Mark E. Fleury

3.1k total citations · 1 hit paper
26 papers, 2.2k citations indexed

About

Mark E. Fleury is a scholar working on Public Health, Environmental and Occupational Health, Economics and Econometrics and Physiology. According to data from OpenAlex, Mark E. Fleury has authored 26 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Public Health, Environmental and Occupational Health, 15 papers in Economics and Econometrics and 7 papers in Physiology. Recurrent topics in Mark E. Fleury's work include Ethics in Clinical Research (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Economic and Financial Impacts of Cancer (8 papers). Mark E. Fleury is often cited by papers focused on Ethics in Clinical Research (14 papers), Health Systems, Economic Evaluations, Quality of Life (13 papers) and Economic and Financial Impacts of Cancer (8 papers). Mark E. Fleury collaborates with scholars based in United States, Switzerland and Australia. Mark E. Fleury's co-authors include Melody A. Swartz, Joseph M. Unger, Dawn L. Hershman, Riha Vaidya, Lori M. Minasian, Alice A. Tomei, Gwendalyn J. Randolph, Jacqueline D. Shields, Federica Boschetti and Andreas H. Zisch and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Mark E. Fleury

25 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

2018 343 citations Joseph M. Unger, Riha Vaidya et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark E. Fleury United States	16	764	599	512	390	373	26	2.2k
Steven E. Canfield United States	24	729 1.0×	646 1.1×	202 0.4×	56 0.1×	127 0.3×	74	5.3k
Heidi V. Russell United States	23	2.3k 3.0×	473 0.8×	149 0.3×	69 0.2×	83 0.2×	74	3.5k
Jacqueline S. Jeruss United States	32	1.3k 1.7×	314 0.5×	1.0k 2.0×	106 0.3×	43 0.1×	106	3.6k
Anthony L. Asher United States	48	2.2k 2.9×	463 0.8×	431 0.8×	44 0.1×	207 0.6×	199	8.4k
Robert A. Lustig United States	33	816 1.1×	394 0.7×	90 0.2×	105 0.3×	28 0.1×	123	4.3k
Sascha Pahernik Germany	33	581 0.8×	414 0.7×	128 0.3×	48 0.1×	61 0.2×	204	4.6k
Alain Brémond France	29	1.3k 1.6×	88 0.1×	305 0.6×	106 0.3×	62 0.2×	117	2.9k
Megan E. Daly United States	38	1.2k 1.5×	136 0.2×	135 0.3×	102 0.3×	36 0.1×	117	4.0k
Soroush Rais‐Bahrami United States	43	628 0.8×	352 0.6×	246 0.5×	62 0.2×	32 0.1×	288	7.5k
Scott H. Kurtzman United States	24	1.1k 1.5×	573 1.0×	58 0.1×	41 0.1×	106 0.3×	58	2.8k

Countries citing papers authored by Mark E. Fleury

Since Specialization

Citations

This map shows the geographic impact of Mark E. Fleury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Fleury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Fleury more than expected).

Fields of papers citing papers by Mark E. Fleury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Fleury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Fleury. The network helps show where Mark E. Fleury may publish in the future.

Co-authorship network of co-authors of Mark E. Fleury

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Fleury. A scholar is included among the top collaborators of Mark E. Fleury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Fleury. Mark E. Fleury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shriver, Sharon P., Sarah S. Long, & Mark E. Fleury. (2025). Views Toward Pharmacogenomic Testing Among Patients With Cancer. JAMA Network Open. 8(8). e2526714–e2526714.

Unger, Joseph M., Lawrence N. Shulman, Matthew A. Facktor, Heidi Nelson, & Mark E. Fleury. (2024). National Estimates of the Participation of Patients With Cancer in Clinical Research Studies Based on Commission on Cancer Accreditation Data. Journal of Clinical Oncology. 42(18). 2139–2148. 33 indexed citations

Shriver, Sharon P., Jeannine S. McCune, Dale Miles, et al.. (2024). Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology. Journal of Clinical Oncology. 42(10). 1181–1192. 9 indexed citations

Fleury, Mark E.. (2023). Consensus recommendations for improving the cancer clinical trial matching environment. Cancer. 130(1). 11–15. 2 indexed citations

Shriver, Sharon P., et al.. (2023). Feasibility of institution‐agnostic, EHR‐integrated regional clinical trial matching. Cancer. 130(1). 60–67. 7 indexed citations

Hurley, Patricia A., et al.. (2023). Provider motivations and barriers to cancer clinical trial screening, referral, and operations: Findings from a survey. Cancer. 130(1). 68–76. 6 indexed citations

Long, Sarah S., et al.. (2022). Association of Remote Technology Use and Other Decentralization Tools With Patient Likelihood to Enroll in Cancer Clinical Trials. JAMA Network Open. 5(7). e2220053–e2220053. 35 indexed citations

Magnuson, Allison, Suanna S. Bruinooge, Harpreet Singh, et al.. (2021). Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group. Clinical Cancer Research. 27(9). 2424–2429. 44 indexed citations

Unger, Joseph M. & Mark E. Fleury. (2021). Nationally representative estimates of the participation of cancer patients in clinical research studies according to the commission on cancer.. Journal of Clinical Oncology. 39(28_suppl). 74–74. 22 indexed citations

10.

Unger, Joseph M., Dawn L. Hershman, Cathee Till, et al.. (2020). “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials. JNCI Journal of the National Cancer Institute. 113(3). 244–257. 152 indexed citations

11.

Tran, George, Matthew Harker, Karen Chiswell, et al.. (2020). Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence. JCO Clinical Cancer Informatics. 4(4). 35–49. 11 indexed citations

12.

Unger, Joseph M. & Mark E. Fleury. (2019). Reimbursing Patients for Participation in Cancer Clinical Trials. JAMA Oncology. 5(7). 932–932. 2 indexed citations

13.

Unger, Joseph M., Dawn L. Hershman, Mark E. Fleury, & Riha Vaidya. (2019). Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncology. 5(3). 326–326. 117 indexed citations

14.

Khan, Tahira, Mark Stewart, Samuel C. Blackman, et al.. (2018). Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols. Therapeutic Innovation & Regulatory Science. 53(2). 270–278. 20 indexed citations

15.

Unger, Joseph M., Riha Vaidya, Dawn L. Hershman, Lori M. Minasian, & Mark E. Fleury. (2018). Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation. JNCI Journal of the National Cancer Institute. 111(3). 245–255. 343 indexed citations breakdown →

16.

Unger, Joseph M., Dawn L. Hershman, Mark E. Fleury, & Riha Vaidya. (2018). Patient comorbid conditions and cancer clinical trial participation.. Journal of Clinical Oncology. 36(15_suppl). 6540–6540. 1 indexed citations

17.

Balogh, Erin P., Carolyn M. Dresler, Mark E. Fleury, et al.. (2013). Reducing Tobacco-Related Cancer Incidence and Mortality: Summary of an Institute of Medicine Workshop. The Oncologist. 19(1). 21–31. 22 indexed citations

18.

Shields, Jacqueline D., et al.. (2007). Autologous Chemotaxis as a Mechanism of Tumor Cell Homing to Lymphatics via Interstitial Flow and Autocrine CCR7 Signaling. Cancer Cell. 11(6). 526–538. 453 indexed citations

19.

Fleury, Mark E., et al.. (2006). Autologous Morphogen Gradients by Subtle Interstitial Flow and Matrix Interactions. Biophysical Journal. 91(1). 113–121. 128 indexed citations

20.

Fleury, Mark E., et al.. (2005). Synergy between interstitial flow and VEGF directs capillary morphogenesisin vitrothrough a gradient amplification mechanism. Proceedings of the National Academy of Sciences. 102(44). 15779–15784. 210 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact